Clinical Trial Update: Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole [Phase 4]

View source ↗

Summary

Phase 4 trial of trimebutine maleate combined with rabeprazole for refractory reflux esophagitis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Reflux Esophagitis

Drugs mentioned

• Rabeprazole (rabeprazole)
• Trimebutine maleate (trimebutine maleate)

Snippet

Sponsor: Xijing Hospital of Digestive Diseases | Conditions: Refractory Reflux Esophagitis | Phase 4 | Status: WITHDRAWN